title: Modulation of inflammatory response improves myocardial infarct healing in rats.
abstract: It is reputed that the ideal therapeutic approaches to treatment of patients with acute coronary syndrome (ACS) and myocardium infarction (MI) should be aimed at the inflammation reaction triggers. This study investigated the effectiveness of the impact of L- 17 compound of the group of 5- phenyl substituted-6H-1,3,4-thiadiazine-2-amines upon the course of experimental MI as compared to the impact of a preparation, officially registered in Russia as an immunomodulator, Tamerit, belonging to phthalhydrazid derivative substance. Acute MI in rats was induced by left coronary artery coagulation. Histological study of the myocardium sections and biochemical analysis has been carried out at the 1st and 7th days of the experimental MI. The conducted investigations have shown that under the action of immunocorrectors the inflammation reaction character changes, exudative/destructive inflammation is replaced by a proliferative-cellular one. Animals' blood biochemical analysis at the background of L-17 and Tamerit introduction has shown a decrease of aminotransferases and lactatedehydrogenases activity in blood as compared to the reference group of animals' indicators, which is evidently caused by epicardial injury of myocardium and lesser amount of the alternative cardiomyocytes. At the same time, no noticeable difference in biochemical characteristics in groups, having been treated to immunomodulators of different chemical composition was identified, which is the sign of the essential similarity of their impact. Thus, immunocorrectors of different chemical groups (Tamerit and compound L17) diminish the volume of initial myocardial infarction and accelerate the granulation processes in course of MI, and represent a new category of treatment agents.
authors.forename: A P
authors.initials: AP
authors.lastname: Sarapultsev
authors.forename: O N
authors.initials: ON
authors.lastname: Chupakhin
authors.forename: P A
authors.initials: PA
authors.lastname: Sarapultsev
authors.forename: M A
authors.initials: MA
authors.lastname: Rantsev
authors.forename: S U
authors.initials: SU
authors.lastname: Medvedeva
authors.forename: L P
authors.initials: LP
authors.lastname: Sidorova
authors.forename: M T
authors.initials: MT
authors.lastname: Abidov
authors.affiliation: Institute of Immunology and Physiology (IIP) of the Ural Division of Russian Academy of Sciences, 106 Pervomaiskaya str, 620219 Ekaterinburg, Russia. a.sarapultsev@gmail.com.
authors.forename: I G
authors.initials: IG
authors.lastname: Danilova
mesh_terms: D000818:Animals; D006834:Hydrazines / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology*; D051381:Rats; D014945:Wound Healing / Q000187:drug effects / Q000276:immunology*
chemical_list: D006834:Hydrazines; C435766:L17 compound